Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Keratin 5 expression defines a niche-supported hierarchy in tubo-ovarian cancer.

Cancer heterogeneity and plasticity·2026

Same author

Referral patterns for genetic counseling and completion of germline testing in patients younger than 50 years with endometrial cancer.

Gynecologic oncology·2026

Same author

DDX5 (p68) and UbE2T as emerging superior cancer therapeutic targets: dual molecular glue target degradation by FL118 for conquering difficult-to-treat cancers.

Journal of experimental & clinical cancer research : CR·2026

Same author

Endometrial Cancer: A Review.

JAMA·2026

Same author

Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Same author

Erratum to When the first hour counts: critical transfusion and transient uncontrolled bleeding in placenta accreta spectrum hysterectomy American Journal of Obstetrics & Gynecology MFM Volume 8, Issue 1, January 2026, 101834.

American journal of obstetrics & gynecology MFM·2026

Search research articles

Related Experiment Video

Updated: Jul 19, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

Acquired factor VIII inhibitor caused by solid tumor malignancy.

Olivia de Bear¹, Karen McLean², Jean Siedel¹

¹Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Michigan Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48109, United States.

Gynecologic Oncology Reports

|August 14, 2023

Summary

Acquired Factor VIII inhibitors can develop in patients with gynecologic and other cancers, presenting as severe bleeding. Treatment involves managing bleeding and suppressing the immune system to eliminate the inhibitor.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Related Experiment Videos

Last Updated: Jul 19, 2025

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models

Published on: January 5, 2024

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

Area of Science:

Hematology
Oncology
Gynecology

Background:

Acquired Factor VIII inhibitors are rare but serious complications.
Malignancies, particularly gynecologic cancers, are an emerging risk factor.

Observation:

Patients may develop inhibitors at any point during their cancer diagnosis or treatment.
Uncontrolled bleeding, unresponsive to standard interventions, is a common clinical presentation.

Findings:

The development of Factor VIII inhibitors is linked to various malignancies.
Effective management necessitates a dual approach: achieving hemostatic control and implementing immunosuppressive therapy.

Implications:

Early recognition of Factor VIII inhibitors in cancer patients is crucial for timely intervention.
Integrating hematologic management into oncologic and gynecologic care pathways can improve patient outcomes.